8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 16, 2007

ANTARES PHARMA, INC.

(Exact name of registrant specified in its charter)

Delaware	1-32302	41-1350192
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

250 Phillips Blvd., Suite 290, Ewing, New Jersey	08618
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone, including area code: (609) 359-3020

Not applicable.

(Former name or former address, if changed since last report)

          Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d)           On January 16, 2007, upon the recommendation of the Governance and Nominating Committee, the Board of Directors (the “Board”) of Antares Pharma, Inc. (the “Company”) appointed Leonard S. Jacob, M.D., Ph.D. as a director of the Company. Dr. Jacob was appointed as a Class I director for a term of office expiring at the Company’s 2008 Annual Meeting of Stockholders. Dr. Jacob’s appointment filled a vacancy on the Board, which now consists of seven members.

Following his appointment, the Company granted Dr. Jacob an option to purchase 20,000 shares of the Company’s Common Stock at an exercise price of $1.23 per share. The option vests in equal quarterly installments over three years and expires on January 15, 2017.

A copy of the Company’s press release announcing Dr. Jacob’s appointment is attached hereto as Exhibit 99.1.

Item9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 – Press Release, dated January 17, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ANTARES PHARMA, INC.
Date: January 22, 2007	By:	/s/ ROBERT F. APPLE
	Name:	Robert F. Apple
	Title:	Senior Vice President and Chief Financial Officer

EXHIBIT INDEX

Exhibit Number Document

99.1 Press Release, dated January 17, 2007.

EX-99

Exhibit 99.1

Antares Pharma, Inc. 707 Eagleview Boulevard, Suite 414 Exton, PA 19341

FOR IMMEDIATE RELEASE Amex: AIS

ANTARES PHARMA ANNOUNCES THE ADDITION OF

LEONARD S. JACOB, M.D., Ph.D. TO

THE BOARD OF DIRECTORS

EWING, NJ, Jan. 17, 2007/Business Wire/ -- Antares Pharma, Inc. (Amex: AIS) has elected Leonard S. Jacob, M.D., Ph.D.to the Company’s Board of Directors.

Dr. Leonard Jacob joins Antares with over 29 years of pharmaceutical industry experience including having founded InKine Pharmaceutical Company Inc. in 1997 and served as Chairman and CEO from its founding until the company was acquired by Salix Pharmaceuticals in 2005. In 1989 Dr. Jacob co-founded Maganin Pharmaceuticals and served as its COO until 1996. From 1980 to 1989 Dr. Jacob served in a variety of executive roles including Worldwide Vice President of SmithKline & French Labs (now Glaxo-SmithKline) and as a member of their Corporate Management Committee. He earned a Ph.D. in pharmacology from Temple University and an M.D. from the Medical College of Pennsylvania (Drexel University College of Medicine). Dr. Jacob currently serves as Chairman of Life Science Advisors, a consulting group to the healthcare industry and is non-executive Chairman of the Board of Bradley Pharmaceuticals, Inc., a specialty pharma company focused principally on niche physician specialty markets in the U.S. He also serves on the Board of the Colon Cancer Alliance and the Board of Overseers for Temple University School of Medicine and is a founding Director of the Jacob Internet fund, a public mutual fund.

Jack E. Stover, President & CEO of Antares, stated, “We welcome Dr. Jacob to our Board of Directors and are pleased to be working with such a seasoned executive. His level of expertise and understanding of all aspects of our industry will be invaluable to Antares as we move forward with execution of our business plan as a specialty pharmaceutical company.”

About Antares Pharma

Antares Pharma is a specialized pharma product development company focused on developing patented drug delivery systems and injectable device engineering capabilities. Antares’ current technology platforms include its ATD™ Advanced Transdermal Delivery system, and its related TecTix™ system for topical and transmucosal delivery, its Easy Tec™ oral fast-melt technology, and subcutaneous injection technology platforms including both Vibex™ disposable mini-needle injection device and Valeo™/Vision® reusable needle-free injection devices. Antares Pharma is committed to leveraging its multiple drug delivery platforms to add value to existing drugs and to create new pharmaceutical products and injectable devices. Overall, Antares’ product pipeline, if approved, will address unmet medical needs by reducing side effect profiles, improving safety, increasing effectiveness, and improving patient compliance and convenience. Antares Pharma

has corporate headquarters in Princeton Crossroads Corporate Center in Ewing, NJ, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

Contacts:

Antares Pharma, Inc., Stephanie M. Baldwin, Robert F. Apple, 609.359.3020

The Trout Group LLC, Brian J. Korb, 212.477.9007

Equity Communications, Steve Chizzik, 908.688.9111